drugset / Trial / NCT05305989
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
Timeline
- Start
- 2022-02-23
- Primary completion
- 2024-06-06
- Completion
- 2024-06-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belumosudil | Small molecule | 200 mg | Oral |
| Subject | Belumosudil | Small molecule | 400 mg | Oral |